Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Sales and Divestitures: 2015-2024

Historic Gains from Sales and Divestitures for Ocular Therapeutix (OCUL) over the last 3 years, with Dec 2024 value amounting to $1.3 million.

  • Ocular Therapeutix's Gains from Sales and Divestitures rose 224.37% to $1.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.3 million, marking a year-over-year increase of 224.37%. This contributed to the annual value of $1.3 million for FY2024, which is 224.37% up from last year.
  • Latest data reveals that Ocular Therapeutix reported Gains from Sales and Divestitures of $1.3 million as of FY2024, which was up 224.37% from $393,805 recorded in FY2023.
  • Ocular Therapeutix's 5-year Gains from Sales and Divestitures high stood at $1.3 million for FY2024, and its period low was $393,805 during FY2023.
  • In the last 2 years, Ocular Therapeutix's Gains from Sales and Divestitures had a median value of $835,602 in 2023 and averaged $835,602.
  • Data for Ocular Therapeutix's Gains from Sales and Divestitures shows a peak YoY skyrocketed of 224.37% (in 2024) over the last 5 years.
  • Ocular Therapeutix's Gains from Sales and Divestitures (Yearly) stood at $393,805 in 2023, then surged by 224.37% to $1.3 million in 2024.